Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

Psoriasis News

the latest news from ipc, industry and others

The United States Food and Drug Administration (FDA) has granted Priority Review for spesolimab for the treatment of flares in patients with generalized pustular psoriasis (GPP), a rare and life-threatening skin disease. If approved, spesolimab would become the first FDA-approved treatment for GPP flares. In clinical trials, spesolimab demonstrated rapid clearance of pustules in adult patients with GPP experiencing a flare. Additionally, the FDA also granted Breakthrough Therapy Designation for spesolimab in the treatment of GPP flares. 

Read the full press release to learn more.

Stay informed

Join the email list to receive the latest information on psoriasis meetings, manuscripts and research.
SUBSCRIBE

now available

COVID-19 Psoriasis Resource Center

Information from around the world on psoriasis and coronavirus to assist dermatologists and the patients they serve

explore now

 

We use cookies on this site to enhance your online experience. By continuing to use this site, you agree to accept cookies.
OK